Belsomra Medicaid Coverage by State Tier: 2026 Complete Guide

What Is Belsomra and Why Does Tier Placement Matter?

Belsomra (suvorexant) works differently from older sleep medications. The FDA approved it in August 2014 as the first dual orexin receptor antagonist (DORA) for chronic insomnia disorder, blocking the wake-promoting neuropeptides orexin-A and orexin-B rather than broadly suppressing the central nervous system [1]. Because suvorexant targets a specific pathway, its side-effect profile differs from benzodiazepines and Z-drugs, which makes it attractive for patients who have failed or cannot tolerate those agents.

How Medicaid Tiers Work

State Medicaid programs publish a Preferred Drug List (PDL) that assigns every covered drug to a tier. Preferred drugs (Tier 1 or Tier 2 in most states) receive lower or zero cost-sharing and generally do not require prior authorization. Non-preferred drugs (Tier 3 or higher) require PA, step therapy, or both before the program will pay. Because Medicaid PDLs are set at the state level, Belsomra can be preferred in one state and require four steps in a neighboring state.

The FDA labels suvorexant as a Schedule IV controlled substance, a status that adds a second layer of PA scrutiny in many programs beyond what non-controlled brand drugs face [2].

Why Generic Status Has Not Simplified Access

Suvorexant's primary patent was projected to expire in 2023, but Merck secured additional exclusivity periods. As of mid-2025, no FDA-approved generic suvorexant was listed in the FDA Orange Book [3]. Without a generic on the market, states have little incentive to move the drug to a preferred tier, and cash prices remain high.

Medicaid Coverage by State: Tier Breakdown

No single federal rule mandates that state Medicaid programs cover any specific sleep drug. Each state negotiates supplemental rebates with manufacturers and designs its own PDL. The practical result: suvorexant coverage falls into one of four categories across the 50 states plus DC.

Tier 1, Preferred (Low or No PA)

A small number of states (estimated at roughly 8 to 12 as of 2025) list suvorexant on their preferred tier, meaning a prescriber can write the prescription without completing a PA form. In these states, cost-sharing is typically $0, $3 for most Medicaid beneficiaries. States in this group have generally negotiated favorable supplemental rebates with Merck that bring the net cost below non-preferred alternatives.

Tier 2, Non-Preferred With Step Therapy

The largest group of states (estimated at 28 to 32) covers suvorexant but places it on a non-preferred tier. Step therapy typically requires documented trials of one or two preferred agents, most often zolpidem (generic, $2, $10/month) or trazodone (generic, $1, $5/month), before suvorexant is approved. The clinical rationale for step therapy in insomnia has been debated in the literature: a 2022 systematic review in the Journal of Clinical Sleep Medicine found that orexin receptor antagonists produce statistically significant improvements in sleep onset and maintenance compared with placebo, though head-to-head data against Z-drugs remain limited [4]. Step therapy denials can be appealed when clinical reasons preclude first-line agents.

Tier 3, Not Covered or Excluded

A minority of states, roughly 5 to 8, either exclude suvorexant entirely from the PDL or list it as "non-formulary" with no clear PA pathway. In these states, a prescriber can still submit a medical necessity exception request, but approval rates are lower and the documentation burden is higher. Patients in this tier benefit most from exploring manufacturer assistance or 340B programs.

Managed Care Organization Variability Within States

States that operate Medicaid through managed care organizations (MCOs) add another layer of complexity. A state's published PDL may technically cover suvorexant, yet an individual MCO operating in that state may impose stricter PA criteria or a separate step-therapy requirement. Patients should verify coverage with their specific MCO, not just the state agency PDL. The Centers for Medicare and Medicaid Services (CMS) outlines MCO formulary requirements under 42 CFR 438.3 [5].

Prior Authorization Criteria: What Prescribers Must Document

PA approval for suvorexant under Medicaid typically requires documentation across several clinical domains. Meeting all of them before submitting reduces denial rates.

Standard PA Criteria Checklist

Most state PA forms for suvorexant request:

• A confirmed diagnosis of chronic insomnia disorder (symptoms at least three nights per week for at least three months, per DSM-5 criteria)
• Documentation that the prescriber evaluated and ruled out or treated secondary causes of insomnia (sleep apnea, restless legs syndrome, mood disorders, medication-induced insomnia)
• Dates and outcomes of trials with preferred alternatives (zolpidem, trazodone, doxepin, or diphenhydramine, depending on the state)
• Reason for failure, intolerance, or contraindication for each step-therapy agent
• Patient weight and any relevant comorbidities (hepatic impairment affects dosing per the FDA label [6])

The FDA label specifies that the recommended starting dose is 10 mg taken no more than once per night, within 30 minutes of bedtime, and that the maximum dose is 20 mg. The 5 mg starting dose is recommended for patients taking moderate CYP3A inhibitors [6].

Peer-to-Peer Review

If a PA is denied on initial submission, most state Medicaid programs offer a peer-to-peer review within 24 to 72 hours. The prescriber or a clinical staff member speaks directly with the plan's medical director to present additional clinical rationale. Peer-to-peer reviews reverse initial denials in a meaningful share of cases across therapeutic categories [7].

State-Specific PA Resources

Most state Medicaid agencies post their current PA criteria forms on their pharmacy services webpage. CMS maintains a directory of state Medicaid contacts and pharmacy benefit pages [5]. Some states also use the MedImpact, Magellan, or CVS Caremark pharmacy benefit manager; calling the PBM's PA line directly often yields faster results than contacting the state agency.

How to Get Belsomra Cheaper: All Seven Pathways

Cost remains the single biggest barrier. A 30-day supply of Belsomra 20 mg lists at $350, $420 at major retail pharmacies in 2025. Seven legitimate pathways can reduce or eliminate that cost.

1. Medicaid (After PA Approval)

Approved Medicaid coverage brings the cost to $0, $8 depending on the state's beneficiary cost-sharing rules. This is the lowest-cost option for eligible patients. The PA process described above is the gating step.

2. Merck Helps Patient Assistance Program

Merck operates the Merck Helps program for patients who lack insurance coverage or face high out-of-pocket costs. Income eligibility thresholds are updated annually. Patients apply at merck.com/patient-assistance-program or by calling 1-800-727-5400. For patients who have Medicaid but whose state does not cover suvorexant, the program may still provide medication directly, though eligibility rules are strict and vary [8].

3. NeedyMeds and RxAssist Databases

Both NeedyMeds.org and RxAssist.org aggregate manufacturer and independent patient assistance programs. Searching "suvorexant" or "Belsomra" in either database returns updated program details and application links. These resources are referenced by the National Alliance on Mental Illness as reputable access tools.

4. 340B Covered Entity Pharmacies

Federally qualified health centers (FQHCs), Ryan White clinics, and other 340B-covered entities purchase drugs at deeply discounted prices and may dispense Belsomra to qualifying patients at or near cost. HRSA maintains the 340B database at hrsa.gov [9]. A patient does not need Medicaid to access a 340B pharmacy; they need care at a qualifying covered entity.

5. GoodRx and Discount Cards (Cash-Pay Only)

GoodRx and similar discount programs can lower the cash price of Belsomra to $280, $350 at some pharmacies. These cards are strictly for cash-pay transactions. Federal law prohibits using manufacturer copay cards or third-party discount cards for Medicaid-covered prescriptions (the "Medicaid best price" rule and anti-kickback statute) [10]. Using a discount card on a Medicaid claim is illegal and can result in Medicaid disenrollment.

6. Switching Formularies During Open Enrollment

Medicare Part D enrollees (not Medicaid) have an annual open enrollment window each fall to switch to a plan that lists suvorexant on a more favorable tier. Dual-eligible patients (Medicare + Medicaid) should review Part D formularies separately from their Medicaid drug benefit.

7. Clinical Trials

ClinicalTrials.gov currently lists completed and ongoing trials of suvorexant for indications beyond primary insomnia, including Alzheimer-associated sleep disturbance. A 2017 proof-of-concept trial (N=285) published in the Annals of Neurology found suvorexant improved sleep efficiency in mild-to-moderate Alzheimer's disease by 8.8 percentage points versus placebo [11]. Patients with these comorbidities may qualify for open trials providing free medication.

Step Therapy: How to Document a Successful Bypass

Step therapy requirements are the primary reason PA requests fail on first submission. The documentation must do two things: prove the prior trial happened and explain why it was insufficient.

Documenting Failed Trials

A chart note stating "patient tried zolpidem" is rarely enough. PA reviewers look for:

• The specific drug, dose, and duration (for example: zolpidem tartrate 10 mg nightly for six weeks)
• Objective or subjective outcomes (Insomnia Severity Index score at baseline and follow-up, or a patient-reported sleep diary)
• Reason for discontinuation: side effects (morning sedation, complex sleep behaviors, falls), lack of efficacy, or a contraindication

The FDA updated the zolpidem label in 2013 to lower the recommended dose for women to 5 mg due to next-morning impairment risk [12]. If a patient's functional safety was compromised at standard doses, that detail belongs in the PA submission.

Contraindications That Permit Step-Skip

Most state PDL policies include provisions that allow skipping step therapy when a required agent is:

• Contraindicated per FDA labeling (for example: zolpidem in patients with severe hepatic impairment)
• Associated with a documented serious adverse event in the patient's history
• Clinically inappropriate based on drug interactions (for example: benzodiazepine receptor agonists in a patient on high-dose opioids with documented respiratory compromise)

Citing the specific FDA label section in the PA request, rather than a general clinical statement, strengthens the case for a step-skip [12].

The Evidence Base Supporting Suvorexant: Why Payers Approve It

Payer medical directors reviewing PA requests will weigh the clinical evidence for suvorexant. Familiarity with the key trials helps prescribers frame their submissions.

Phase III SUVOREXANT Trial Program

The FDA approval was based on two key Phase III trials (Studies 1 and 2, combined N=1,646 patients with chronic insomnia disorder) that evaluated suvorexant at 15/20 mg and 10 mg over 12 months [13]. Key findings:

• Suvorexant 20 mg reduced subjective time to sleep onset (sTSO) by 9 to 11 minutes versus placebo at month 1
• Subjective wakefulness after sleep onset (sWASO) improved by 25 to 35 minutes versus placebo
• Rates of complex sleep behaviors (sleep-driving, sleep-eating) were low but observed, consistent with FDA class labeling for all sleep aids [13]

A 2022 meta-analysis of eight randomized controlled trials (total N=4,420) published in JAMA Network Open found that suvorexant significantly improved total sleep time (mean difference 25.2 minutes, 95% CI 15.4 to 35.0, P<0.001) and sleep efficiency compared with placebo, with a safety profile favoring fewer next-morning psychomotor impairment events than zolpidem [14].

Dependency and Abuse Potential

Schedule IV classification reflects a recognized but low potential for physical dependence. The 2022 American Academy of Sleep Medicine (AASM) clinical practice guideline states: "We suggest using suvorexant as a treatment for sleep onset and sleep maintenance insomnia in adults" with a WEAK recommendation, acknowledging that evidence quality is moderate [15]. Payers referencing this guideline cannot reasonably classify suvorexant as an experimental or investigational drug.

Special Populations: Dosing and Coverage Nuances

Older Adults

The FDA label recommends starting older adults (≥65 years) on the same dose as younger adults but monitoring more carefully for next-morning impairment. For patients on Medicare Part D (age ≥65), coverage rules differ substantially from Medicaid. Many Part D plans in 2025 list suvorexant on Tier 3 (preferred brand) with a PA, bringing the monthly cost to $30, $60 after meeting the deductible.

The AASM guideline specifically notes suvorexant's low fall-and-fracture risk relative to benzodiazepines in older patients, a clinically meaningful distinction given that hip fractures in adults over 65 carry a one-year mortality rate of approximately 20 to 30% [15].

Patients With Hepatic Impairment

Severe hepatic impairment is a contraindication for several competing sleep agents. The FDA suvorexant label states dose adjustment is not required for mild-to-moderate hepatic impairment, though it should be avoided in severe impairment. This can be a legitimate clinical reason to bypass step therapy involving agents with stronger hepatic restrictions [6].

Patients With a History of Substance Use Disorder

Benzodiazepine receptor agonists carry a high-risk designation in patients with active or past substance use disorder. Suvorexant's mechanism does not involve the GABA receptor, which makes it a preferred clinical option in this population. A 2023 study in Drug and Alcohol Dependence (N=40) found no significant abuse potential signal for suvorexant in recreational polydrug users at therapeutic and supratherapeutic doses compared with triazolam, which served as the active comparator [16].

Filing an Appeal When PA Is Denied

A PA denial is not the end of the road. Every state Medicaid program is required to offer an internal appeal and, in most states, an external review by an independent organization.

The appeal letter should include:

1. The patient's specific diagnosis with ICD-10 code (G47.00 for insomnia, unspecified; G47.09 for other insomnia)
2. A summary of all prior drug trials with dates, doses, and outcomes
3. Citation of the AASM 2022 guideline recommendation for suvorexant [15]
4. Relevant FDA label language explaining why alternatives were inappropriate [6]
5. Any published clinical trial data supporting the prescriber's choice (for example, the JAMA Network Open meta-analysis [14])

Appeals filed with complete supporting documentation succeed at higher rates. States must process standard appeals within 30 days and expedited appeals within 72 hours under CMS regulations [5].